FAKTOR-OPTIONSSCHEIN - CHARLES RIVER LABS INTL Stock

Certificat

DE000MG3DBU1

Market Closed - Börse Stuttgart 15:57:43 2024-06-14 EDT
14.74 EUR +8.06% Intraday chart for FAKTOR-OPTIONSSCHEIN - CHARLES RIVER LABS INTL
Current month-10.62%
1 month+39.18%
Date Price Change
24-06-14 14.74 +8.06%
24-06-13 13.64 +5.17%
24-06-12 12.97 -1.97%
24-06-11 13.23 +3.93%
24-06-10 12.73 +15.73%

Delayed Quote Börse Stuttgart

Last update June 14, 2024 at 03:57 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Issuer Morgan Stanley
WKN MG3DBU
ISINDE000MG3DBU1
Date issued 2024-04-30
Strike 247.9 $
Maturity Unlimited
Parity 2.43 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 16.67
Lowest since issue 7.98
Spread 0.3
Spread %2.01%

Company Profile

Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Sector
-
More about the company

Ratings for Charles River Laboratories International, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Charles River Laboratories International, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
212.4 USD
Average target price
263.1 USD
Spread / Average Target
+23.85%
Consensus